Key Updates
British American Tobacco has surged +6.68% since the last report to £4,569, accelerating YTD gains to +8.42% and recovering substantially from the previous decline to £4,283. This rally follows strong full-year 2025 results that exceeded market expectations, with pretax profit jumping to £9.86 billion from £3.54 billion and adjusted operating profit reaching £11.89 billion versus consensus of £11.29 billion. The company's new categories revenue grew 7% to £3.62 billion, while the Velo nicotine pouch brand gained US market share against competitors. Despite positive earnings momentum, BAT faces mounting legal challenges with nearly 200 American terrorism victims filing suit over alleged North Korea sanctions violations, alongside ongoing competitive pressures in the US vape market from illegal imports.
Current Trend
BAT has demonstrated strong momentum across all timeframes: +2.15% (1d), +4.94% (5d), +7.56% (1m), +4.01% (6m), and +8.42% YTD. The stock has recovered from the £4,283 level reported on February 16th, breaking through resistance at £4,381 and £4,484 to reach £4,569. This represents a decisive reversal from the -2.24% decline in the previous report and establishes a clear uptrend with higher lows at £4,283, £4,381, and £4,484. The current price sits approximately 6.7% above the recent support level, indicating strengthening bullish sentiment following the February 12th earnings release. Trading volumes have likely increased on the positive earnings surprise, with the stock outperforming the broader FTSE 100 which hit record highs during this period.
Investment Thesis
The investment thesis centers on BAT's successful transformation into a diversified next-generation products company while maintaining robust cash generation from traditional tobacco operations. The company's new categories portfolio—comprising vapor, heated tobacco, and oral nicotine pouches—now generates £3.62 billion in revenue with 7% constant currency growth, demonstrating accelerating adoption of reduced-risk alternatives. BAT's Velo brand is capturing US market share from Philip Morris's Zyn and Altria's On!, positioning the company competitively in the high-growth nicotine pouch segment. The traditional cigarette business continues delivering substantial cash flows with adjusted operating profit of £11.89 billion, supporting a 2% dividend increase to 245.04 pence per share and providing financial flexibility for innovation investment. Regulatory tailwinds from potential US import blocks on unauthorized vapes could reduce the 70% illegal market share, benefiting BAT's authorized products. However, the thesis faces headwinds from the South African factory closure due to 75% illicit market penetration, ongoing terrorism-related litigation seeking substantial damages, and intensifying competition from Philip Morris's aggressive investment plans of up to $1.6 billion in next-generation products.
Thesis Status
The thesis has strengthened materially with the February 12th full-year results exceeding expectations across all key metrics. Pretax profit of £9.86 billion significantly surpassed the prior year's £3.54 billion, while adjusted operating profit of £11.89 billion beat consensus by 5.3%. The 7% new categories revenue growth validates the transformation strategy, particularly with Velo's US market share gains against Philip Morris demonstrating competitive momentum. The 2% dividend increase to 245.04 pence confirms management's confidence in cash generation sustainability. However, two significant risks have materialized: the South African factory closure highlights the severity of illicit trade erosion in key markets, while the terrorism lawsuit involving 200 victims seeking damages over North Korea sanctions violations introduces substantial legal and reputational risk beyond the $629 million already paid in 2023. The potential US import block on unauthorized vapes represents a significant positive catalyst that could materialize in 2027, though the CEO acknowledges impact timing uncertainty. Overall, the operational thesis is tracking ahead of expectations, but legal and regulatory uncertainties have increased.
Key Drivers
BAT's full-year 2025 results delivered a pretax profit surge to £9.86 billion from £3.54 billion, with adjusted operating profit of £11.89 billion exceeding consensus forecasts by £600 million. The company's new categories revenue rose 7% to £3.62 billion, with the Velo nicotine pouch brand gaining US market share through higher nicotine strengths and promotional strategies. A potential US import block on unauthorized vapes could reduce the illegal market by one-third, though implementation is unlikely before 2027 following ITC determination in March and 60-day presidential review. The South African factory closure reflects the 75% illicit market penetration that has undermined compliant producers and cost billions in lost excise revenue. A lawsuit from nearly 200 terrorism victims seeks damages for allegedly financing North Korea's ballistic missile programs through a joint venture that generated $418 million in banking transactions. Competitor Philip Morris forecasts 11-13% EPS growth for 2026 but faces Zyn market share losses, while planning up to $1.6 billion in growth investments.
Technical Analysis
BAT has established a strong uptrend with three ascending support levels: £4,283 (February 16), £4,381 (February 13), and £4,484 (February 12). The current price of £4,569 represents a +6.68% advance since the last report and sits approximately 6.7% above the nearest support at £4,283. The stock has outperformed the FTSE 100 index, which reached new record highs during this period but gained only 0.1% on February 12 when BAT advanced following earnings. Short-term momentum indicators are positive across all timeframes: +2.15% (1d), +4.94% (5d), and +7.56% (1m), with the 6-month gain of +4.01% suggesting sustained medium-term strength. The YTD performance of +8.42% has recovered from the compressed +1.64% level on February 16, indicating renewed buying interest. Resistance likely exists around the £4,600-£4,650 range, with psychological resistance at £4,750-£5,000. The stock's ability to maintain gains above £4,484 will be critical for confirming the bullish breakout, while a decline below £4,381 would signal weakening momentum.
Bull Case
- Exceptional earnings beat with pretax profit reaching £9.86 billion versus £3.54 billion prior year, and adjusted operating profit of £11.89 billion exceeding consensus by £600 million, demonstrating robust operational execution. Source: Wall Street Journal
- New categories revenue grew 7% at constant currencies to £3.62 billion with Velo gaining US market share against Philip Morris's Zyn through competitive nicotine strengths and promotional strategies, validating transformation strategy. Source: Reuters
- Potential US import block on unauthorized vapes could reduce the 70% illegal market by approximately one-third following ITC determination in March, creating significant market share opportunity for BAT's authorized products. Source: Reuters
- Dividend increased 2% to 245.04 pence per share, demonstrating management confidence in sustainable cash generation and commitment to shareholder returns despite transformation investments. Source: Morningstar
- Philip Morris faces competitive pressures with Zyn market share losses and provided no specific US growth guidance despite planning $1.6 billion investments, suggesting BAT's Velo momentum may continue. Source: Reuters
Bear Case
- Nearly 200 American terrorism victims filed lawsuit seeking substantial damages for allegedly financing North Korea's weapons programs with $418 million in banking transactions, beyond the $629 million already paid in 2023 penalties. Source: PR Newswire
- South African factory closure reflects 75% illicit market penetration that has undermined the business model in a key market, with CEO warning about enforcement weaknesses costing billions in lost tax revenue. Source: Bloomberg
- Group revenue declined 1% to £25.61 billion due to 3.1% foreign exchange headwinds, with traditional cigarette volumes continuing structural decline offsetting new categories growth. Source: Wall Street Journal
- Philip Morris achieved 2024-2026 targets ahead of schedule with smoke-free products reaching 41.5% of revenues and serving 43 million consumers, demonstrating aggressive competitive positioning with superior scale. Source: Business Wire
- US vape import block impact unlikely before 2027 due to long supply chains and large existing inventories, delaying potential market share recapture by at least 12 months despite favorable ITC ruling. Source: Reuters